Celgene Corporation (CELG) : Strategic Wealth Advisors Groupinc. added new position in Celgene Corporation during the most recent quarter end. The investment management firm now holds 85,641 shares of Celgene Corporation which is valued at $9.1 Million , the company said in a statement filed on May 25, 2016 with the SEC.Celgene Corporation makes up approximately 2.90% of Strategic Wealth Advisors Groupinc.’s portfolio.
Other Hedge Funds, Including , Whalerock Point Partners boosted its stake in CELG in the latest quarter, The investment management firm added 4,445 additional shares and now holds a total of 24,410 shares of Celgene Corporation which is valued at $2.6 Million. Celgene Corporation makes up approx 1.10% of Whalerock Point Partners’s portfolio.Ontario Teachers Pension Plan Board reduced its stake in CELG by selling 1,568 shares or 30.28% in the most recent quarter. The Hedge Fund company now holds 3,611 shares of CELG which is valued at $361,678.First Foundation Advisors reduced its stake in CELG by selling 723 shares or 2.87% in the most recent quarter. The Hedge Fund company now holds 24,458 shares of CELG which is valued at $2.4 Million. Celgene Corporation makes up approx 0.18% of First Foundation Advisors’s portfolio.Alliancebernstein boosted its stake in CELG in the latest quarter, The investment management firm added 22,014 additional shares and now holds a total of 2,953,794 shares of Celgene Corporation which is valued at $295.9 Million. Celgene Corporation makes up approx 0.26% of Alliancebernstein’s portfolio. Spark Investment Management added CELG to its portfolio by purchasing 13,600 company shares during the most recent quarter which is valued at $1.4 Million. Celgene Corporation makes up approx 0.14% of Spark Investment Management’s portfolio.
Celgene Corporation opened for trading at $104.48 and hit $106.44 on the upside on Wednesday, eventually ending the session at $106.02, with a gain of 0.47% or 0.5 points. The heightened volatility saw the trading volume jump to 28,51,558 shares. Company has a market cap of $82,123 M.
On the company’s financial health, Celgene Corporation reported $1.32 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $1.27. The company had revenue of $2511.60 million for the quarter, compared to analysts expectations of $2577.08 million. The company’s revenue was up 20.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.07 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Company shares were Reiterated by Sun Trust Rbsn Humphrey on Apr 29, 2016 to “Buy”, Firm has raised the Price Target to $ 147 from a previous price target of $145 .
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.